Shimura Masahiko

Shimura Masahiko, Sasaki Shotaro, Nonaka Ryota, Kashiwagi Ikumi, Yasuda Kanako, Noma Hidetaka et al.

Faricimab treatment for DME significantly altered aqueous Ang-1/2 levels. A higher Ang-1/2 ratio correlated with less residual edema, suggesting it's a useful biomarker for treatment response.

Utsumi Takuya, Noma Hidetaka, Yasuda Kanako, Goto Hiroshi, Shimura Masahiko

Ranibizumab for diabetic macular edema reduced aqueous VEGF, PlGF, PDGF-AA, and IP-10. Baseline levels of PlGF, MCP-1, and IL-6 correlated with visual improvement, suggesting these are therapeutic targets.

Noma Hidetaka, Mimura Tatsuya, Yasuda Kanako, Shimura Masahiko

Bevacizumab for BRVO macular edema reduced sVEGFR-1, VEGF, MCP-1, and IL-6. Macular edema improvement correlated with sVEGFR-1 and PDGF-AA inhibition, suggesting these are key therapeutic targets and response indicators.

Noma Hidetaka, Mimura Tatsuya, Yasuda Kanako, Shimura Masahiko

This study found aqueous sVEGFR-1 levels correlate with retinal thickness and inflammatory factors in CRVO macular edema, suggesting potential for anti-VEGFR-1 therapy.

Nakazawa Toru, Shimura Masahiko, Ryu Morin, Himori Noriko, Nitta Fumihiko, Omodaka Kazuko et al.

This study found normal tension glaucoma patients with generalized cup enlargement optic discs had faster visual field progression, suggesting disc appearance can inform management.

Shimura Masahiko, Yasuda Kanako, Nakazawa Toru, Shiono Takashi, Sakamoto Taiji, Nishida Kohji

Drug reflux during posterior subtenon triamcinolone for diabetic macular edema leads to less edema reduction and significantly higher intraocular pressure elevation, requiring more glaucoma treatment.

Shimura Masahiko, Nakazawa Toru, Yasuda Kanako, Shiono Takashi, Nishida Kohji

Pre-treating diabetic macular edema with subtenon triamcinolone before laser improved vision and foveal thickness, prevented transient worsening, and allowed for lower laser intensity, offering clinical advantages.

Kudo Hideyo, Nakazawa Toru, Shimura Masahiko, Takahashi Hidetoshi, Fuse Nobuo, Kashiwagi Kenji et al.

Latanoprost protected rat retinal ganglion cells from damage induced by NMDA or optic nerve injury, suggesting potential neuroprotective benefits for glaucoma patients.